Choose your preferred way to stay informed of new case launches and settlement deadlines
4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than 35.8% in afternoon trading on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
In order to be eligible to join the FDMT class action lawsuit, you must have incurred a loss on shares of 4D Molecular Therapeutics purchased during the class period listed above.
TOP
